Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark McCamish

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Pharmacogenomics|October 24, 2006
Perspectives on development of a combination pharmacogenomic diagnostic and drug productMark McCamish, Raquel Izumi
Expert Review of Clinical Pharmacology|December 14, 2012
The rise of the biosimilarMark McCamish, Gillian Woollett
Clinical Pharmacology and Therapeutics|February 10, 2012
The state of the art in the development of biosimilarsMark McCamish, Gillian Woollett
Mabs|March 29, 2011
Worldwide experience with biosimilar developmentMark McCamish, Gillian Woollett
The American Journal of Managed Care|July 19, 2017
Biosimilars: biologics that meet patients' needs and healthcare economicsMark McCamish, William Yoon, James McKay
European Journal of Internal Medicine|November 15, 2003
The decline in plasma leptin in response to calorie restriction predicts the effects of adjunctive leptin treatment on body weight in humansJaap Fogteloo, Edo Meinders, Marijke Frölich, et al.
Current Medical Research and Opinion|January 31, 2017
The totality-of-the-evidence approach to the development and assessment of GP2015, a proposed etanercept biosimilarVibeke Strand, Giampiero Girolomoni, Martin Schiestl, et al.
Diabetes Technology & Therapeutics|November 24, 2007
Clinical predictors of glycosylated hemoglobin response to thiazolidinedione therapyRaquel Izumi, Janet Hurt, Kevin C Maki, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|September 29, 2004
Impact of anemia on hospitalization time, charges, and mortality in patients with heart failureRobert J Nordyke, John J Kim, George A Goldberg, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Pharmacogenomics|October 24, 2006
Perspectives on development of a combination pharmacogenomic diagnostic and drug productMark McCamish, Raquel Izumi
Expert Review of Clinical Pharmacology|December 14, 2012
The rise of the biosimilarMark McCamish, Gillian Woollett
Clinical Pharmacology and Therapeutics|February 10, 2012
The state of the art in the development of biosimilarsMark McCamish, Gillian Woollett
Mabs|March 29, 2011
Worldwide experience with biosimilar developmentMark McCamish, Gillian Woollett
The American Journal of Managed Care|July 19, 2017
Biosimilars: biologics that meet patients' needs and healthcare economicsMark McCamish, William Yoon, James McKay
European Journal of Internal Medicine|November 15, 2003
The decline in plasma leptin in response to calorie restriction predicts the effects of adjunctive leptin treatment on body weight in humansJaap Fogteloo, Edo Meinders, Marijke Frölich, et al.
Current Medical Research and Opinion|January 31, 2017
The totality-of-the-evidence approach to the development and assessment of GP2015, a proposed etanercept biosimilarVibeke Strand, Giampiero Girolomoni, Martin Schiestl, et al.
Diabetes Technology & Therapeutics|November 24, 2007
Clinical predictors of glycosylated hemoglobin response to thiazolidinedione therapyRaquel Izumi, Janet Hurt, Kevin C Maki, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|September 29, 2004
Impact of anemia on hospitalization time, charges, and mortality in patients with heart failureRobert J Nordyke, John J Kim, George A Goldberg, et al.
Pageof 1